ACE2 and COVID-19: Understanding the physical mechanism responsible for the mutation-induced changes in the RBD’s binding affinity with the receptor angiotensin converting enzyme 2 (ACE2) and antibodies is the “urgent challenge” in the development of preventive measures, vaccines, and therapeutic antibodies against the COVID-19 pandemic [8,9,10,11,12,13,14,15].